{"created":"2023-05-15T14:59:50.311204+00:00","id":81203,"links":{},"metadata":{"_buckets":{"deposit":"ca2c0595-6596-4aa2-9f81-717380333c47"},"_deposit":{"created_by":1,"id":"81203","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"81203"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00081203","sets":["7"]},"author_link":["906092","906093","906094"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-03","bibliographicIssueDateType":"Issued"},"bibliographic_titles":[{"bibliographic_title":"厚生労働科学研究費補助金　地域医療基盤開発推進研究事業　令和元年度　総括・分担研究報告書"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"近年、核医学治療あるいは標的アイソトープ治療が盛んとなり、α線核種を標識した製剤によるTRT製剤が大きな注目を浴びている。世界的にはα線TRT製剤が多数開発されており、国内でも次世代α線核種アスタチン-211の医学利用に期待が寄せられ、開発中である。\n本研究では、211At　MABGによる転移性悪性褐色細胞腫に対する\nTRTの臨床応用を進めるに当たって必要な退出基準の策定を目的として検討を進めた。\n","subitem_description_type":"Abstract"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"906092","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"右近, 直之"}],"nameIdentifiers":[{"nameIdentifier":"906093","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"906094","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"「アスタチン-211(211At)標識MABG療法：転移性悪性褐色細胞腫に対する新規核医学治療（RI内容療法）における安全管理に関する研究（退出基準の作成）」","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"「アスタチン-211(211At)標識MABG療法：転移性悪性褐色細胞腫に対する新規核医学治療（RI内容療法）における安全管理に関する研究（退出基準の作成）」"}]},"item_type_id":"10004","owner":"1","path":["7"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-12-04"},"publish_date":"2020-12-04","publish_status":"0","recid":"81203","relation_version_is_last":true,"title":["「アスタチン-211(211At)標識MABG療法：転移性悪性褐色細胞腫に対する新規核医学治療（RI内容療法）における安全管理に関する研究（退出基準の作成）」"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:09:52.060098+00:00"}